Extended Lipid Panel Assay
Device Facts
| Record ID | K181373 |
|---|---|
| Device Name | Extended Lipid Panel Assay |
| Applicant | Laboratory Corporation of America Holdings |
| Product Code | CHH · Clinical Chemistry |
| Decision Date | Oct 18, 2018 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1175 |
| Device Class | Class 1 |
| Attributes | AI/ML |
AI Performance
| Output | Acceptance | Observed | Dev DS | Test DS |
|---|---|---|---|---|
| Total Cholesterol | Difference of less than or equal ±10% between test sample and control for interference; deviation from linearity < 10% | Repeatability %CV: 0.9% - 1.6%; Within-lab %CV: 1.1% - 1.6%; Reproducibility %CV: 2.1% - 3.6%; Linearity Slope: 1.010, R2: 1.000 | Not specified | Method comparison study: 281 samples; Precision study: 3 levels of pooled serum; Linearity study: 15 samples |
| Triglycerides | Difference of less than or equal ±10% between test sample and control for interference; deviation from linearity < 10% | Repeatability %CV: 1.0%; Within-lab %CV: 1.0% - 1.4%; Reproducibility %CV: 2.1% - 3.4%; Linearity Slope: 0.999, R2: 1.000 | Not specified | Method comparison study: 270 samples; Precision study: 3 levels of pooled serum; Linearity study: 17 samples |
| HDL Cholesterol | Difference of less than or equal ±10% between test sample and control for interference; deviation from linearity < 10% | Repeatability %CV: 1.3% - 2.4%; Within-lab %CV: 1.4% - 2.8%; Reproducibility %CV: 2.1% - 4.6%; Linearity Slope: 1.063, R2: 1.000 | Not specified | Method comparison study: 15575 samples; Precision study: 3 levels of pooled serum; Linearity study: 12 samples |
| Apolipoprotein B | Difference of less than or equal ±10% between test sample and control for interference; deviation from linearity < 10% | Repeatability %CV: 1.1% - 1.2%; Within-lab %CV: 1.9% - 2.4%; Reproducibility %CV: 3.7% - 6.7%; Linearity Slope: 0.985, R2: 0.999 | Not specified | Method comparison study: 266 samples; Precision study: 3 levels of pooled serum; Linearity study: 13 samples |
Indications for Use
The Extended Lipid Panel Assay is an in vitro diagnostic test for quantitative determination of total cholesterol, high density lipoprotein cholesterol, and triglycerides in human serum and plasma, and apolipoprotein B in human serum. Values for total cholesterol, high density lipoprotein cholesterol, triglycerides and apolipoprotein B are quantified by the Vantera Clinical Analyzer. Total cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood, lipid, and lipoprotein metabolism disorders. High density lipoprotein cholesterol measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. Triglyceride measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders. Apolipoprotein B measurements are used in the diagnosis and treatment of lipid disorders and atherosclerosis. For in vitro diagnostic use only. For prescription use only.
Device Story
The Extended Lipid Panel Assay utilizes 400 MHz proton NMR spectroscopy to analyze human serum or plasma samples. The device measures proton signals (methylene and methyl) from lipids within lipoproteins. Spectral data is processed via a Partial Least Squares (PLS) regression model to derive analyte concentrations (Total Cholesterol, HDL-C, Triglycerides, ApoB). The system is operated by professionals in a clinical laboratory setting using the Vantera® Clinical Analyzer. The output provides quantitative lipid values, which clinicians use to diagnose and manage lipid metabolism disorders, atherosclerosis, and related endocrine or metabolic conditions. This automated analysis replaces traditional enzymatic colorimetric assays, offering a high-throughput method for lipid profiling.
Clinical Evidence
No clinical trials were performed. Evidence is based on analytical performance studies including precision (repeatability, within-lab, and reproducibility), linearity, and method comparison. Method comparison against predicate methods (N=266-281 for most analytes, N=15,575 for HDL) showed high correlation (R=0.980–0.997). Bias at medical decision points was within acceptable limits. Interference testing confirmed no significant interference (≤±10%) from common endogenous and exogenous substances.
Technological Characteristics
The system utilizes 400 MHz proton NMR spectroscopy. Consumables include NMR Diluent 1 (aqueous solution with Na2EDTA, CaCl2, KCl, NaHPO4·7H2O), Wash Solution (Triton X-100, LiquiNox), and NMR Reference Standard (trimethyl acetate sodium salt). The Vantera Clinical Analyzer is an automated laboratory instrument. The assay is quantitative, utilizing Partial Least Squares regression for spectral analysis. It is designed for serum and plasma specimens.
Indications for Use
Indicated for quantitative determination of total cholesterol, HDL cholesterol, and triglycerides in human serum/plasma, and apolipoprotein B in human serum, for diagnosis and treatment of lipid/lipoprotein metabolism disorders, atherosclerosis, diabetes, and liver/renal diseases.
Regulatory Classification
Identification
A cholesterol (total) test system is a device intended to measure cholesterol in plasma and serum. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders.
Predicate Devices
- Roche Diagnostics, COBAS Integra Cholesterol Gen.2 (k031824)
- Roche Diagnostics, HDL-Cholesterol plus 2nd Generation (k012286)
- Boehringer Mannheim, Triglycerides GPO Without Free Glycerol (k873049)
- Dade Behring, Dimension Vista APOB Flex reagent cartridge (k063608)
Related Devices
- K113830 — VANTERA CLINICAL ANALYZER · Liposcience · Aug 30, 2012
Submission Summary (Full Text)
{0}
1
# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE
A. 510(k) Number:
k181373
B. Purpose for Submission:
New device
C. Measurand:
Total cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides and apolipoprotein B
D. Type of Test:
Quantitative, Nuclear Magnetic Resonance (NMR) spectroscopy assay
E. Applicant:
Laboratory Corporation of America Holdings
F. Proprietary and Established Names:
Extended Lipid Panel Assay
G. Regulatory Information:
| Regulation | Classification | Product Code | Panel |
| --- | --- | --- | --- |
| 21 CFR 862.1175
Cholesterol (total) Test System | Class I, meets the limitations of exemptions 21 CFR 862.9(c)(4) | CHH: Enzymatic esterase--oxidase, Cholesterol | Chemistry (75) |
| 21 CFR 862.1475
Lipoprotein Test System | Class I, meets the limitations of exemptions 21 CFR 862.9(c)(4) | LBS: LDL & VLDL precipitation, cholesterol via esterase-oxidase, HDL | Chemistry (75) |
| 21 CFR 862.1705
Triglyceride Test System | Class I, meets the limitations of exemptions 21 CFR 862.9(c)(4) | CDT: lipase hydrolysis/glycerol kinase enzyme, Triglycerides | Chemistry (75) |
{1}
| Regulation | Classification | Product Code | Panel |
| --- | --- | --- | --- |
| 21 CFR 862.1475
Lipoprotein Test System | Class I, meets the limitations of exemptions 21 CFR 862.9(c)(4) | MSJ: Apolipoproteins | Chemistry (75) |
H. Intended Use:
1. Intended uses:
See indications for use below.
2. Indications for use:
The Extended Lipid Panel Assay is an in vitro diagnostic test for quantitative determination of total cholesterol, high density lipoprotein cholesterol, and triglycerides in human serum and plasma, and apolipoprotein B in human serum. Values for total cholesterol, high density lipoprotein cholesterol, triglycerides and apolipoprotein B are quantified by the Vantera Clinical Analyzer.
Total cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood, lipid, and lipoprotein metabolism disorders.
High density lipoprotein cholesterol measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.
Triglyceride measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders.
Apolipoprotein B measurements are used in the diagnosis and treatment of lipid disorders and atherosclerosis.
3. Special conditions for use statements:
For in vitro diagnostic use only.
For prescription use only.
4. Special instrument requirements:
Vantera Clinical Analyzer
I. Device Description:
The test system includes the following consumables and instrument:
NMR Diluent 1 - A ready to use aqueous solution (Na₂EDTA, CaCl₂, KCl, NaHPO₄·7H₂O) to dilute specimens.
{2}
Wash Solution - A ready to use aqueous solution (Triton X-100, LiquiNox, sodium bicarbonate, sodium carbonate).
NMR Reference Standard - A ready to use aqueous solution (trimethyl acetate sodium salt, $\mathrm{NA}_2\mathrm{EDTA}$ , $\mathrm{CaCl}_2$ , KCl, and $\mathrm{D}_2\mathrm{O}$ ) for a daily calibration of the instrument.
Vantera Clinical Analyzer - The Vantera Clinical Analyzer is an automated laboratory analyzer which quantitates clinical samples using $400\mathrm{MHz}$ proton NMR. The Vantera Clinical Analyzer was cleared in k113830.
Liquichek Lipids Controls - Two levels of pooled human serum based control material.
# J. Substantial Equivalence Information:
1. Predicate device names:
Total Cholesterol: k031824
Roche Diagnostics, COBAS Integra Cholesterol Gen.2
HDL Cholesterol: k012286
Roche Diagnostics, HDL-Cholesterol plus 2nd Generation
Triglyceride: k873049
Boehringer Mannheim, Triglycerides GPO Without Free Glycerol
Apolipoprotein B: k063608
Dade Behring, Dimension Vista APOB Flex reagent cartridge
2. Predicate $510(\mathbf{k})$ numbers:
See predicate device names in section J.1 above.
3. Comparison with predicate:
| Similarities and Differences | | |
| --- | --- | --- |
| Item | Candidate Device, Total cholesterol, Extended Lipid Panel Assay k181373 | Predicate Device, Total Cholesterol k031824 |
| Intended Use | For the quantitative determination of total cholesterol. | Same |
| Use type | Prescription use | Same |
| Specimens | Serum and plasma | Same |
| Analytical method | 400 MHz proton NMR | Enzymatic colorimetric assay |
{3}
| Similarities and Differences | | |
| --- | --- | --- |
| Item | Candidate Device, HDL cholesterol, Extended Lipid Panel Assay k181373 | Predicate Device, HDL-Cholesterol k012286 |
| Intended Use | For the quantitative determination of HDL cholesterol. | Same |
| Use type | Prescription use | Same |
| Specimens | Serum and plasma | Same |
| Analytical method | 400 MHz proton NMR | Enzymatic colorimetric assay |
| Similarities and Differences | | |
| --- | --- | --- |
| Item | Candidate Device, Triglycerides, Extended Lipid Panel Assay k181373 | Predicate Device, Triglycerides k873049 |
| Intended Use | For the quantitative determination of triglycerides. | Same |
| Use type | Prescription use | Same |
| Specimens | Serum and plasma | Same |
| Analytical method | 400 MHz proton NMR | Enzymatic colorimetric assay |
| Similarities and Differences | | |
| --- | --- | --- |
| Item | Candidate Device Apolipoprotein B, Extended Lipid Panel Assay k181373 | Predicate Device, Dimension Vista Apolipoprotein B Flex reagent cartridge k063608 |
| Intended Use | For the quantitative determination of Apolipoprotein B. | Same |
| Use type | Prescription use | Same |
| Specimens | Serum | Serum and Plasma |
| Analytical method | 400 MHz proton NMR | Nephelometric immunoassay |
# K. Standard/Guidance Document Referenced:
Clinical and Laboratory Standards Institute (CLSI) Guideline EP5-A3: Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline -Third Edition.
CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline.
CLSI EP7-A2: Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition.
{4}
CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline - Second Edition.
# L. Test Principle:
The methodology of the test system involves measurement of a $400\mathrm{MHz}$ proton NMR spectrum on a plasma or serum sample. The NMR spectra generated by the Vantera Clinical Analyzer can be used to simultaneously quantify total cholesterol, triglycerides, HDL cholesterol, and apolipoprotein B. The sample is diluted 1:2 with NMR Diluent 1. The NMR spectrum consists of multiple proton signals from the triglycerides, cholesteryl esters and free cholesterol present in chylomicrons, VLDL, LDL and HDL in the combined methylene and methyl region $(0.56 - 1.40\mathrm{ppm})$ . The NMR signals from these lipoproteins have distinctive frequencies and line shapes, and the amplitude of the NMR signal is proportional to the concentration. The quantitative results are generated based on a Partial Least Squares regression method using spectral information.
# M. Performance Characteristics:
# 1. Analytical performance:
# a. Precision/Reproducibility:
The precision performance of the Extended Lipid Panel Assay was evaluated following the recommendations in the CLSI EP5-A3 guideline.
#1 Repeatability (Within-run precision)
Repeatability was assessed using 3 levels of pooled serum samples, and tested in one run of 20 replicates on one instrument by one operator. The results are summarized below:
| Analyte | Pool | Mean, (mg/dL) | SD | %CV |
| --- | --- | --- | --- | --- |
| Total cholesterol | Low | 159 | 2.6 | 1.6 |
| | Medium | 196 | 2.6 | 1.3 |
| | High | 276 | 2.6 | 0.9 |
| Triglycerides | Low | 128 | 1.0 | 1.0 |
| | Medium | 158 | 1.6 | 1.0 |
| | High | 317 | 3.1 | 1.0 |
| HDL cholesterol | Low | 37 | 0.9 | 2.4 |
| | Medium | 50 | 0.8 | 1.6 |
| | High | 91 | 1.2 | 1.3 |
| Apolipoprotein B | Low | 77 | 0.9 | 1.2 |
| | Medium | 106 | 1.1 | 1.1 |
| | High | 134 | 1.4 | 1.1 |
{5}
#2 Within-laboratory precision
Within-laboratory precision was assessed using 3 levels of pooled serum samples, and tested in 2 replicates per run, 2 runs per day for 20 days for a total of 80 measurements per level. One operator conducted the study using one lot of reagents using one instrument. The results are summarized below:
| Analyte | Pool | Mean, (mg/dL) | SD | %CV |
| --- | --- | --- | --- | --- |
| Total cholesterol | Low | 167 | 2.7 | 1.6 |
| | Medium | 197 | 2.8 | 1.4 |
| | High | 280 | 3.2 | 1.1 |
| Triglycerides | Low | 131 | 1.8 | 1.4 |
| | Medium | 161 | 1.9 | 1.2 |
| | High | 320 | 3.1 | 1.0 |
| HDL cholesterol | Low | 37 | 1.0 | 2.8 |
| | Medium | 49 | 1.2 | 2.3 |
| | High | 92 | 1.3 | 1.4 |
| Apolipoprotein B | Low | 79 | 1.9 | 2.4 |
| | Medium | 109 | 2.4 | 2.2 |
| | High | 138 | 2.6 | 1.9 |
# 3 Reproducibility
A reproducibility study was performed at three intended use sites using 3 levels of pooled serum samples. At each site with one instrument and one operator, the samples were tested in 2 replicates per run, 6 runs per day for 5 days for a total of 60 measurements per level. Each site performed testing using the same three lots of reagents. The precision analysis used a mixed effects model with reagent lot, site/instrument/operator, day, run, and within-run as random effects. The results are summarized below.
| | | | Between lot | | Between site | | Reproducibility | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Analyte | Pool | Mean, mg/dL | SD | %CV | SD | %CV | SD | %CV |
| TC | Low | 142 | 0 | 0 | 3.86 | 2.7% | 5.16 | 3.6% |
| | Med | 214 | 0 | 0 | 2.71 | 1.3% | 4.78 | 2.1% |
| | High | 316 | 0 | 0 | 4.03 | 1.3% | 6.58 | 2.1% |
| TG | Low | 107 | 0 | 0 | 1.33 | 1.2% | 3.66 | 3.4% |
| | Med | 170 | 0 | 0 | 1.82 | 1.1% | 5.14 | 3.0% |
| | High | 296 | 0.49 | 0.2% | 0 | 0 | 6.16 | 2.1% |
| HDL | Low | 36 | 0 | 0 | 0.80 | 2.2% | 1.66 | 4.6% |
| | Med | 52 | 0.11 | 0.2% | 1.80 | 3.4% | 2.21 | 4.2% |
| | High | 80 | 0.23 | 0.3% | 1.81 | 2.3% | 1.67 | 2.1% |
| ApoB | Low | 85 | 0.38 | 0.4% | 4.96 | 5.8% | 5.73 | 6.7% |
| | Med | 115 | 0.25 | 0.2% | 4.34 | 3.8% | 4.85 | 4.2% |
| | High | 164 | 0 | 0 | 4.83 | 2.9% | 6.16 | 3.7% |
{6}
In some instances when analyzing the variance by mixed effects model the result was a negative number, and therefore the contribution was considered negligible and the variance set to 0.
# b. Linearity/assay reportable range:
A linearity study was conducted on the Extended Lipid Panel Assay following the recommendations in the CLSI EP06-A guideline. The linearity was assessed using pooled serum samples spanning the target analyte concentration range which were prepared by combining volumes from three pools; low pool, mid pool, and high pool. A total of 15 samples for total cholesterol, 13 samples for Apolipoprotein B, 17 samples for triglycerides, and 12 samples for HDL cholesterol were prepared for the linearity assessment. For each sample 4 replicates were tested by one operator using one instrument. The mean values of four replicates of each pool were compared to the expected target values to determine the deviation from linearity. For all samples the deviation from linearity was less than $10\%$ . The linear regression results are given in the table below:
| Analyte | Slope | Intercept | R2 |
| --- | --- | --- | --- |
| Total cholesterol | 1.010 | -1.851 | 1.000 |
| Triglycerides | 0.999 | -1.086 | 1.000 |
| HDL cholesterol | 1.063 | -1.925 | 1.000 |
| Apolipoprotein B | 0.985 | -1.668 | 0.999 |
Based on these results, the sponsor concluded that the linearity data supported the claimed analytical measurement range for total cholesterol, triglycerides, HDL cholesterol, and apolipoprotein B:
66 to $868\mathrm{mg / dL}$ for total cholesterol
35 to $950\mathrm{mg / dL}$ for triglycerides
14 to $152\mathrm{mg / dL}$ for HDL cholesterol
35 to $366\mathrm{mg / dL}$ for apolipoprotein B
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
# Traceability:
The Extended Lipid Panel Assay for total cholesterol, HDL cholesterol, triglycerides, and apolipoproteins B is traceable to internal instrument standards.
The Extended Lipid Panel Assay is CRMLN certified for total cholesterol using serum samples. The total cholesterol assay is traceable to the National Reference System for Cholesterol.
{7}
d. Detection limit:
Determination of the Limit of Blank (LoB), Limit of Detection (LoD) and Limit of Quantification (LoQ) for the Extended Lipid Panel Assay were conducted following the recommendations in the CLSI EP17-A2 guideline.
Limit of Blank:
The LoB study followed a classical protocol and utilized 5 different pools of human serum albumin solution free of analyte. Each pool was tested in 4 replicates over a three day period using one instrument by one operator for a total 60 measurements. Using the parametric approach, LoB was derived from the $95^{\text{th}}$ percentile of a normal distribution.
Limit of Detection:
The LoD study followed a classical protocol and utilized 5 different serum pools which were diluted 20-fold using human serum albumin solution. Each pool was tested in 4 replicates per day on one instrument by one operator for three days for a total of 60 measurements. The data was analyzed to calculate the LoD using a parametric analysis recommended in the CLSI guideline EP17-A2.
Limit of Quantification:
The LoQ study followed an approach similar to the LoD study. Five 5 serum pools with low concentrations were tested in replicates of 4 over 3 days on one instrument and one operator for a total of 12 measurements per pool. The sponsor defined the LoQ as the lowest analyte concentration where the $\% \mathrm{CV}$ was $\leq 20\%$ . The detection limit results are summarized as follows:
| Analyte | LoB | LoD | LoQ |
| --- | --- | --- | --- |
| Total cholesterol, mg/dL | 18.9 | 22.2 | 23.5 |
| Triglycerides, mg/dL | 11.9 | 13.8 | 15.2 |
| HDL cholesterol, mg/dL | 11.3 | 12.9 | 12.9 |
| Apolipoprotein B, mg/dL | 15.7 | 17.9 | 17.9 |
The LoQ values support the sponsors claimed measurement ranges of:
| Analyte | Measurement range |
| --- | --- |
| Total cholesterol | 66 - 868 mg/dL |
| Triglycerides | 35 - 950 mg/dL |
| HDL cholesterol | 14 - 152 mg/dL |
| Apolipoprotein B | 35 - 366 mg/dL |
{8}
# e. Analytical specificity:
Interference testing on the Extended Lipid Panel Assay was evaluated following the recommendations in the CLSI EP7-A2 guideline. Serum samples at two analyte concentrations near the medical decision concentrations were evaluated for each substance. The samples were divided into two aliquots: control with no added interferent and test with added interferent. Each sample was measured in 2 replicates. The study tested for possible interference from common endogenous substances, and exogenous substances such as medications or supplements likely to be used by the target patient population. The interferent concentrations were selected using the criteria recommended in CLSI EP7-A2. The following tables list the concentration of each substance at which no significant interference was detected; defined as a difference of less than or equal $\pm 10\%$ between the test sample and control.
| Total cholesterol - Substances tested | Highest concentration tested at which no significant interference was observed. |
| --- | --- |
| Exogenous Substances | |
| Atorvastatin | 4.9 mg/dL |
| Fenofibrate | 4.5 mg/dL |
| Acetylsalicylic Acid | 66 mg/dL |
| Acetaminophen | 20 mg/dL |
| Naproxen Sodium | 42 mg/dL |
| Ibuprofen Sodium Salt | 59 mg/dL |
| Hydrochlorothiazide | 0.6 mg/dL |
| Metoprolol Tartrate | 1.5 mg/dL |
| Nifedipine | 0.041 mg/dL |
| Enalaprilat Dihydrate | 0.037 mg/dL |
| Hydralazine | 19 mg/dL |
| Metformin | 65 mg/dL |
| Salicylic Acid | 61 mg/dL |
| Clopidogrel | 18 mg/dL |
| Furosemide | 6.3 mg/dL |
| Glipizide | 0.22 mg/dL |
| Heparin Sodium | 3035 mU/mL |
| Isosorbide Dinitrate | 0.016 mg/dL |
| Menhaden Oil | 241 mg/dL |
| | |
| Endogenous Substances | |
| Bilirubin, unconjugated | 20 mg/dL |
| Bilirubin, conjugated | 34 mg/dL |
| Creatinine | 5.5 mg/dL |
| Hemoglobin | 219 mg/dL |
| Urea | 263 mg/dL |
| Uric acid | 24 mg/dL |
| Albumin | 5987 mg/dL |
| Triglycerides | 500 mg/dL |
{9}
| Triglycerides - Substances tested | Highest concentration tested at which no significant interference was observed. |
| --- | --- |
| Exogenous Substances | |
| Atorvastatin | 4.9 mg/dL |
| Fenofibrate | 4.5 mg/dL |
| Acetylsalicylic Acid | 66 mg/dL |
| Acetaminophen | 20 mg/dL |
| Naproxen Sodium | 56 mg/dL |
| Ibuprofen Sodium Salt | 29 mg/dL |
| Hydrochlorothiazide | 0.65 mg/dL |
| Metoprolol Tartrate | 1.5 mg/dL |
| Nifedipine | 0.041 mg/dL |
| Enalaprilat Dihydrate | 0.037 mg/dL |
| Hydralazine | 19 mg/dL |
| Metformin | 65 mg/dL |
| Salicylic Acid | 61 mg/dL |
| Clopidogrel | 18 mg/dL |
| Furosemide | 6.3 mg/dL |
| Glipizide | 0.22 mg/dL |
| Heparin Sodium | 3035 mU/mL |
| Isosorbide Dinitrate | 0.016 mg/dL |
| Menhaden Oil | 241 mg/dL |
| | |
| Endogenous Substances | |
| Bilirubin, unconjugated | 20 mg/dL |
| Bilirubin, conjugated | 34 mg/dL |
| Creatinine | 5.6 mg/dL |
| Hemoglobin | 219 mg/dL |
| Urea | 263 mg/dL |
| Uric acid | 24 mg/dL |
| Albumin | 5987 mg/dL |
| HDL cholesterol - Substances tested | Highest concentration tested at which no significant interference was observed. |
| --- | --- |
| Exogenous Substances | |
| Atorvastatin | 4.9 mg/dL |
| Fenofibrate | 4.6 mg/dL |
| Acetylsalicylic Acid | 66 mg/dL |
| Acetaminophen | 20.0 mg/dL |
| Naproxen Sodium | 28 mg/dL |
| Ibuprofen Sodium Salt | 44 mg/dL |
| Hydrochlorothiazide | 0.65 mg/dL |
| Metoprolol Tartrate | 1.5 mg/dL |
| Nifedipine | 0.041 mg/dL |
| Enalaprilat Dihydrate | 0.037 mg/dL |
| Hydralazine | 19 mg/dL |
{10}
| HDL cholesterol - Substances tested | Highest concentration tested at which no significant interference was observed. |
| --- | --- |
| Metformin | 65 mg/dL |
| Salicylic Acid | 61 mg/dL |
| Clopidogrel | 18 mg/dL |
| Furosemide | 6.3 mg/dL |
| Glipizide | 0.22 mg/dL |
| Heparin Sodium | 3035 mU/mL |
| Isosorbide Dinitrate | 0.016 mg/dL |
| Menhaden Oil | 242 mg/dL |
| | |
| Endogenous Substances | |
| Bilirubin, unconjugated | 20 mg/dL |
| Bilirubin, conjugated | 34 mg/dL |
| Creatinine | 5.6 mg/dL |
| Hemoglobin | 219 mg/dL |
| Urea | 263 mg/dL |
| Uric acid | 24 mg/dL |
| Albumin | 7493 mg/dL |
| Triglycerides | 1135 mg/dL |
| Apolipoprotein B - Substances tested | Highest concentration tested at which no significant interference was observed. |
| --- | --- |
| Exogenous Substances | |
| Atorvastatin | 4.9 mg/dL |
| Fenofibrate | 4.5 mg/dL |
| Acetylsalicylic Acid | 66 mg/dL |
| Acetaminophen | 20.4 mg/dL |
| Naproxen Sodium | 28 mg/dL |
| Ibuprofen Sodium Salt | 44 mg/dL |
| Hydrochlorothiazide | 0.65 mg/dL |
| Metoprolol Tartrate | 1.5 mg/dL |
| Nifedipine | 0.041 mg/dL |
| Enalaprilat Dihydrate | 0.033 mg/dL |
| Hydralazine | 19 mg/dL |
| Metformin | 65 mg/dL |
| Salicylic Acid | 61 mg/dL |
| Clopidogrel | 9.5 mg/dL |
| Furosemide | 6.3 mg/dL |
| Glipizide | 0.23 mg/dL |
| Heparin Sodium | 3035 mU/mL |
| Isosorbide Dinitrate | 0.016 mg/dL |
| Menhaden Oil | 241 mg/dL |
| Acetylcysteine | 125 mg/dL |
| Ampicillin | 6.1 mg/dL |
| Ascorbic Acid | 6.2 mg/dL |
{11}
12
| Apolipoprotein B - Substances tested | Highest concentration tested at which no significant interference was observed. |
| --- | --- |
| Calcium Dobesilate | 30 mg/dL |
| Cyclosporine | 6.1 mg/dL |
| Cefoxitin | 70 mg/dL |
| Levodopa | 1.6 mg/dL |
| Methyldopa | 1.6 mg/dL |
| Metronidazole | 12 mg/dL |
| Doxycycline | 3.1 mg/dL |
| Rifampin (Rifampicin) | 34 mg/dL |
| | |
| Endogenous Substances | |
| Bilirubin, unconjugated | 20 mg/dL |
| Bilirubin, conjugated | 34 mg/dL |
| Creatinine | 5.5 mg/dL |
| Hemoglobin | 219 mg/dL |
| Urea | 263 mg/dL |
| Uric acid | 24 mg/dL |
| Albumin | 5986 mg/dL |
| Triglycerides | 633 mg/dL |
f. Assay cut-off:
Not applicable.
2. Comparison studies:
a. Method comparison with predicate device:
To establish the accuracy of the Extended Lipid Panel Assay, a method comparison study was conducted to evaluate the analytical agreement to a comparator method for each of the 4 analytes. Serum samples were tested in singlicate on the Vantera Clinical Analyzer and the comparator methods. The results of the method comparison studies are summarized as follows.
Deming regression analysis
| | N | Slope | Intercept | R | Range |
| --- | --- | --- | --- | --- | --- |
| Total Cholesterol | 281 | 0.974 | 7.27 | 0.992 | 71 to 859 mg/dL |
| Triglycerides | 270 | 0.980 | -3.86 | 0.997 | 36 to 939 mg/dL |
| HDL Cholesterol | 15575 | 1.000 | 0.789 | 0.985 | 15 to 151 mg/dL |
| Apolipoprotein B | 266 | 0.970 | -1.01 | 0.980 | 36 to 344 mg/dL |
{12}
# Predicted Bias at Medical Decision Points
An estimate of the predicated bias at the medical decision points was calculated as the percent difference between the regression line and the unity line at each medical decision point.
| Predicated Bias at Medical Decision Points (95% CI) | | |
| --- | --- | --- |
| Total cholesterol | 200 mg/dL | 240 mg/dL |
| | 1.0% (-0.7% to 2.7%) | 0.4% (-1.0% to 1.8%) |
| | | |
| Triglycerides | 150 mg/dL | 200 mg/dL |
| | -4.5% (-5.7% to -3.4%) | -3.9% (-4.7% to -3.0%) |
| | | |
| HDL Cholesterol | 40 mg/dL | 60 mg/dL |
| | 2.0% (1.7% to 2.3%) | 1.3% (1.1% to 1.5%) |
| | | |
| Apolipoprotein B | 90 mg/dL | 130 mg/dL |
| | -4.1% (-6.5% to -1.8%) | -3.8% (-5.4% to -2.2%) |
# b. Matrix comparison:
A matrix comparison study was conducted on matched specimens collected in 4 different blood collection tube types; see table below. The NMR LipoTube (cleared in k960858) was the comparator in the study and was used to collect specimens for all the above analytical studies.
| Specimen Type | Collection Tube |
| --- | --- |
| Plasma | EDTA |
| Plasma | Sodium heparin |
| Serum | Plain |
| Serum | Gel barrier / NMR LipoTube |
EDTA plasma, sodium heparin plasma, and serum samples (47 native and 5 contrived) were analyzed in singlicate on the Vantera Clinical Analyzer for total cholesterol, HDL cholesterol, triglycerides, and Apolipoprotein B. These were compared to the results from testing specimens collected using the NMR LipoTube measured in duplicate. The matrix comparison results were analyzed by Deming regression and are given in the table below:
| Analyte | Collection tube | Intercept (95% CI) | Slope (95% CI) | R2 | Concentration range, mg/dL |
| --- | --- | --- | --- | --- | --- |
| Total cholesterol | Na Heparin | 6.12 (3.37, 8.87) | 0.985 (0.974, 0.996) | 0.998 | 79-798 |
| | Plain | 10.29 (7.14, 13.44) | 0.963 (0.951, 0.976) | 0.998 | |
{13}
| Analyte | Collection tube | Intercept (95% CI) | Slope (95% CI) | R2 | Concentration range, mg/dL |
| --- | --- | --- | --- | --- | --- |
| | | | | | |
| Triglycerides | EDTA | 1.75 (-1.85, 5.36) | 0.938 (0.925, 0.952) | 0.997 | 42 - 934 |
| | Na Heparin | 4.28 (2.09, 6.47) | 0.947 (0.938, 955) | 0.999 | |
| | Plain | 2.19 (-0.21, 4.59) | 0.985 (0.976, 994) | 0.999 | |
| | | | | | |
| HDL cholesterol | EDTA | 0.68 (-0.44, 1.80) | 0.956 (0.938, 0.974) | 0.996 | 22 - 153 |
| | Na Heparin | 0.66 (-0.49, 1.82) | 0.997 (0.978, 1.01) | 0.996 | |
| | Plain | 1.51 (0.37, 2.66) | 0.994 (0.975, 1.01) | 0.996 | |
| | | | | | |
| Apolipoprotein B | Plain | 5.67 (3.71, 7.63) | 0.967 (0.950, 983) | 0.996 | 33 - 360 |
Based on the study data, serum collected from the NMR LipoTube or a plain tube is the acceptable specimen type when simultaneously quantifying all four analytes. Sodium heparin plasma is an acceptable specimen type for total cholesterol, HDL cholesterol, and triglycerides. EDTA plasma is an acceptable specimen type for HDL cholesterol and triglycerides. The product labeling states that serum and plasma specimens drawn in gel barrier collection tubes other than the NMR LipoTube are unsuitable for analysis and should not be used.
# 3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
# 4. Clinical cut-off:
Not applicable.
{14}
# 5. Expected values/Reference range:
The reference values for total cholesterol, HDL cholesterol, and triglycerides were identified in the labeling as:
| Analyte | Concentration, mg/dL | Adult Treatment Panel III Classification |
| --- | --- | --- |
| Total cholesterol | < 200 | Desirable |
| | 200 - 239 | Borderline high |
| | ≥ 240 | High |
| HDL cholesterol | < 40 | Low |
| | ≥ 60 | High |
| Triglycerides | < 150 | Normal |
| | 150 - 199 | Borderline high |
| | 200 - 499 | High |
| | ≥ 500 | Very high |
Source: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, Vol. 285, 2486-2497; 2001.
The reference values for Apolipoprotein B were identified in the labeling as:
| | Concentration, mg/dL | Classification |
| --- | --- | --- |
| Apolipoprotein B | < 90 | Low |
| | 90 - 130 | Intermediate |
| | > 130 | High |
Source: Grundy SM. Low Density Lipoprotein, Non-High Density Lipoprotein, and Apolipoprotein B as Targets for Lipid-Lowering Therapy. Circ. 2002;106:2526-9
# N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Parts 801 and 809, as applicable.
# O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
